Mladsi D, Zhou X, Mader G, Sanon M, Wang J, Barnett C, Willey C, Seliger S. Mortality risk in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2024 Feb 16;25(1):56. doi: 10.1186/s12882-024-03484-3
Danese D, Goss D, Romano (DeMuro) C, Gupta C. Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study. BMC Nephrol. 2023 Oct 26;24(1):319. doi: 10.1186/s12882-023-03365-1
Mader G, Mladsi D, Sanon M, Purser M, Barnett CL, Oberdhan D, Watnick T, Seliger S. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC Nephrol. 2022 Oct 18;23(1):334. doi: 10.1186/s12882-022-02956-8
Williamson DB, Haltiwanger RS. Identification, function, and biological relevance of POGLUT2 and POGLUT3. Biochem Soc Trans. 2022 Apr 29;50(2):1003-12. doi: 10.1042/BST20210850
Henderson GE, Ewing M, Kuczynski KJ, Cadigan RJ, Waltz M, Butterfield RM, Rini C, Weck K, Berg JS, Edwards TP. Development and validation of a measure of comprehension of genomic screening-negative results (CoG-NR). Eur J Hum Gene. 2020 Oct;28(10):1394-402. doi: 10.1038/s41431-020-0657-1
Garcia-Esteve L, Torres A, Navarro P, Aguado J, Ascaso C. Maternidad the planned y psicomorbilidad: un riesgo evitable / Unplanned pregnancy and psychological morbidity: an avoidable risk. Fac Med Barc. 2005 Jul;32(3):111-8.